Kourosh Nazari, MD
Ophthalmology · Deland, FLNPI 1881685741
Payments from drug & device makers
Across 38 payments — averaging $105.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$2K
- Sight Sciences, Inc.$848
- Alcon$726
- Glaukos Corporation$150
- Apellis Pharmaceuticals, Inc.$52
- Kala Pharmaceuticals, Inc.$35
- plus $82 from 5 others
What the payments were for
- Food & beverage$1,89347%
- Other$2,12053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 2 | $2,120 |
| Sight Sciences, Inc. | 8 | $848 |
| Alcon | 18 | $726 |
| Glaukos Corporation | 1 | $150 |
| Apellis Pharmaceuticals, Inc. | 2 | $52 |
| Kala Pharmaceuticals, Inc. | 2 | $35 |
| NEW World Medical,inc. | 1 | $21 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Amgen | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$2,120
- OMNI(R) SURGICAL SYSTEM (US)$809
- KXL System$150
- SION SURGICAL INSTRUMENT$150
- Centurion$150
- PanOptix$136
How this compares
$4,013 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 20 | $16,243 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $7,459 |
| LumiganBimatoprost | 17 | $5,959 |
| Prednisolone Acetate | 149 | $4,452 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 53 | $2,328 |
| Latanoprost | 174 | $826 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 59 | $691 |
| Ofloxacin | 28 | $467 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $418 |
| Ketorolac Tromethamine | 11 | $102 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Deland
- Kevin BarberDeland$1.2M
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.